Literature DB >> 34338743

Two Models of Legalization of Psychedelic Substances: Reasons for Concern.

William R Smith1,2, Paul S Appelbaum3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34338743      PMCID: PMC8753745          DOI: 10.1001/jama.2021.12481

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  10 in total

1.  Trial of Psilocybin versus Escitalopram for Depression.

Authors:  Robin Carhart-Harris; Bruna Giribaldi; Rosalind Watts; Michelle Baker-Jones; Ashleigh Murphy-Beiner; Roberta Murphy; Jonny Martell; Allan Blemings; David Erritzoe; David J Nutt
Journal:  N Engl J Med       Date:  2021-04-15       Impact factor: 91.245

2.  Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.

Authors:  Peter S Hendricks; Christopher B Thorne; C Brendan Clark; David W Coombs; Matthew W Johnson
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

3.  Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016.

Authors:  Magdalena Cerdá; Christine Mauro; Ava Hamilton; Natalie S Levy; Julián Santaella-Tenorio; Deborah Hasin; Melanie M Wall; Katherine M Keyes; Silvia S Martins
Journal:  JAMA Psychiatry       Date:  2020-02-01       Impact factor: 21.596

4.  Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Authors:  Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-08-30       Impact factor: 4.153

5.  MDMA-related presentations to the emergency departments of the European Drug Emergencies Network plus (Euro-DEN Plus) over the four-year period 2014-2017.

Authors:  Roberta Noseda; Yasmin Schmid; Irene Scholz; Evangelia Liakoni; Matthias E Liechti; Paul I Dargan; David M Wood; Alison M Dines; Christopher Yates; Fridtjof Heyerdahl; Knut E Hovda; Isabelle Giraudon; Alessandro Ceschi
Journal:  Clin Toxicol (Phila)       Date:  2020-07-17       Impact factor: 4.467

Review 6.  Trends over time in adult cannabis use: A review of recent findings.

Authors:  Deborah Hasin; Claire Walsh
Journal:  Curr Opin Psychol       Date:  2021-03-20

7.  Psychotic disorders hospitalizations associated with cannabis abuse or dependence: A nationwide big data analysis.

Authors:  Manuel Gonçalves-Pinho; Miguel Bragança; Alberto Freitas
Journal:  Int J Methods Psychiatr Res       Date:  2019-12-05       Impact factor: 4.035

Review 8.  Psychedelics and Psychedelic-Assisted Psychotherapy.

Authors:  Collin M Reiff; Elon E Richman; Charles B Nemeroff; Linda L Carpenter; Alik S Widge; Carolyn I Rodriguez; Ned H Kalin; William M McDonald
Journal:  Am J Psychiatry       Date:  2020-02-26       Impact factor: 18.112

9.  MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.

Authors:  Jennifer M Mitchell; Michael Bogenschutz; Alia Lilienstein; Charlotte Harrison; Sarah Kleiman; Kelly Parker-Guilbert; Marcela Ot'alora G; Wael Garas; Casey Paleos; Ingmar Gorman; Christopher Nicholas; Michael Mithoefer; Shannon Carlin; Bruce Poulter; Ann Mithoefer; Sylvestre Quevedo; Gregory Wells; Sukhpreet S Klaire; Bessel van der Kolk; Keren Tzarfaty; Revital Amiaz; Ray Worthy; Scott Shannon; Joshua D Woolley; Cole Marta; Yevgeniy Gelfand; Emma Hapke; Simon Amar; Yair Wallach; Randall Brown; Scott Hamilton; Julie B Wang; Allison Coker; Rebecca Matthews; Alberdina de Boer; Berra Yazar-Klosinski; Amy Emerson; Rick Doblin
Journal:  Nat Med       Date:  2021-05-10       Impact factor: 53.440

10.  Psychedelics and mental health: a population study.

Authors:  Teri S Krebs; Pål-Ørjan Johansen
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

  10 in total
  2 in total

1.  Legalization of Psychedelic Substances-Reply.

Authors:  William R Smith; Paul S Appelbaum
Journal:  JAMA       Date:  2021-12-21       Impact factor: 157.335

2.  Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes.

Authors:  Richard Matzopoulos; Robert Morlock; Amy Morlock; Bernard Lerer; Leonard Lerer
Journal:  Front Psychiatry       Date:  2022-01-03       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.